VivoSeq
Other

Cholestasis

16

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Cholestasis is an emerging landscape with 16 programs across 9 companies. The most active players are AbbVie, Albireo, an Ipsen Company, Intercept Pharmaceuticals. 4 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

76/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 2A

Albireo, an Ipsen Company

1 program

Phase 2I

Intercept Pharmaceuticals

1 program

Phase 3Z

Zhejiang Hisun Pharmaceutical Co. Ltd.

2 programs

ApprovedAstraZeneca logo

AstraZeneca

1 program

ApprovedF

Fresenius

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

22

clinical trials

Completed13 · 59%
Withdrawn3 · 14%
Unknown status2 · 9%
Recruiting1 · 5%
No longer available1 · 5%
Terminated1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

22 trials

The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis
Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT07250854·15 enrolled
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Active, not recruiting·GSK logoGSK·Phase 3·NCT04167358·242 enrolled
Fibrates in Pediatric Cholestasis
Completed·—·Phase 2·NCT03586674·50 enrolled
Cholestasis Reversal: Efficacy of IV Fish Oil
Completed·—·Phase 2/3·NCT00910104·91 enrolled
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
Completed·UUniversity of Michigan·N/A·NCT00004414·252 enrolled
Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
Completed·UUniversity of Nebraska·Phase 2·NCT00826020·72 enrolled
Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
Completed·—·N/A·NCT01173159·10 enrolled
Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates
Completed·—·Phase 2/3·NCT00846963·26 enrolled
Preventing Cholestasis Using SMOFLipid®
Completed·MMedical University of Vienna·Phase 4·NCT01585935·230 enrolled
Cholestasis Prevention: Efficacy of IV Fish Oil
Completed·—·Phase 1·NCT00512629·19 enrolled
Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants
Completed·—·N/A·NCT00004410·50 enrolled
Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates
Completed·IIndiana University·Phase 3·NCT03387579·24 enrolled
A4250, an IBAT Inhibitor in Pediatric Cholestasis
Completed·AAlbireo·Phase 2·NCT02630875·24 enrolled
Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
Completed·UUniversity of Rochester·Phase 3·NCT01555957·40 enrolled
Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis
Completed·AArthur J De Lorimier·Phase 1/2·NCT01601652·12 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)